Clinical Trials Directory

Trials / Conditions / Keratosis

Keratosis

14 registered clinical trials studyying Keratosis — 1 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEfficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Fo
NCT07273656
University Hospital, LillePhase 3
UnknownIdentification of Oral Lesions Through an Autofluorescence System
NCT05942794
Federico II UniversityN/A
UnknownEfficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
NCT06206681
Sun Yat-sen University—
CompletedStudy to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of
NCT05060237
Biofrontera Bioscience GmbHPhase 1
UnknownA Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures
NCT04336514
University Health Network, TorontoN/A
WithdrawnA Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
NCT02813902
Massachusetts General HospitalPhase 1
WithdrawnStudy of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection
NCT02851693
Centre Hospitalier Universitaire de Saint EtienneN/A
UnknownTobacco Cessation Intervention Study for Oral Diseases
NCT02737176
Association for the Japanese Academy of Maxillofacial ImplantsN/A
CompletedStudy to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
NCT00239135
PeplinPhase 2
CompletedThe Effect of Efudex Treatment on Photoaged Skin
NCT00121511
University of MichiganN/A
CompletedOpen-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
NCT00116649
Graceway Pharmaceuticals, LLCPhase 4
CompletedStudy to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Ar
NCT00115154
Graceway Pharmaceuticals, LLCPhase 4
CompletedStudy of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
NCT00110682
Derm Research @ 888 Inc.Phase 4
Completed1-Year Follow up to the 1473-IMIQ Study
NCT00114023
Graceway Pharmaceuticals, LLC—